However, despite the increased exposure to asparaginase in the present study, clinically significant adverse events related to pegaspargase (i.e., venous thromboembolism, hemorrhage, hepatic failure, pancreatitis, and hypersensitivity reactions) were not statistically different from those seen with CLAG-M, and the response rate to this potent regimen was promising. Here, ASPG is linked to hypersensitivity.